Nonprofit · EIN 13-4128413
GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC
Tax-exempt · NEW YORK, NY 10005
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| December 31, 2024 | 990 | $63,732,557 | $61,508,783 | $2,223,774 | $204,316,428 | $28,006,599 | $176,309,829 |
| December 31, 2023 | 990 | $60,240,486 | $55,378,579 | $4,861,907 | $197,319,541 | $25,619,991 | $171,699,550 |
Financial details: 990 for the year ended December 31, 2024
Revenue
- Contributions, gifts and grants
- $52,737,212
- of which government grants
- $35,728,256
- Program service revenue
- $0
- Investment income
- $9,675,203
- Royalties
- $387,789
- Net gain from sales of assets
- $3,656,406
- Other revenue
- $1,320,142
Expenses
- Grants and similar amounts paid
- $359,938
- Compensation of officers, directors and key employees
- $4,529,643
- Other salaries and wages
- $10,141,255
- Salaries, compensation and benefits (total)
- $17,962,003
- Professional fundraising fees
- $0
- Legal fees
- $822,060
- Accounting fees
- $142,596
- Occupancy
- $1,178,518
- Travel
- $904,955
- Depreciation
- $263,420
- Program services (functional)
- $54,417,744
- Management and general (functional)
- $5,733,341
- Fundraising (functional)
- $1,357,698
Balance sheet and other
- Total assets, start of year
- $197,319,541
- Total assets, end of year
- $204,316,428
- Total liabilities, end of year
- $28,006,599
- Net assets, end of year
- $176,309,829
- Land, buildings and equipment
- $1,320,475
- Publicly traded securities
- $80,443,114
- Net assets without donor restrictions
- $176,309,829
- Gross receipts
- $202,456,266
- Employees
- 50
- Volunteers
- 11
- Year formed
- 2000
- State of legal domicile
- DE
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended December 31, 2024, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| DR MELVIN SPIGELMAN | PRESIDENT/CEO Trustee or director, Officer | 45 | $939,703 | $113,233 |
| DR NADER FOTOUHI | SR. VP, CHIEF SCIENTIFIC OFFICER Key employee | 45 | $565,207 | $118,405 |
| DR EUGENE SUN | SR. VP, RESEARCH & DEVELOPMENT Key employee | 45 | $580,925 | $93,318 |
| MARIA BEUMONT | VP, CHIEF MEDICAL OFFICER Key employee | 45 | $497,709 | $86,293 |
| COLLEEN PERO | SECRETARY/CAO Officer | 45 | $470,044 | $71,098 |
| ROBERT LORETTE | SR. VP, BUSINESS DEVELOPMENT Highest-paid employee | 45 | $448,954 | $87,286 |
| ANGELA VANDERPLOEG | TREASURER/CFO Officer | 45 | $421,854 | $104,371 |
| SANDEEP JUNEJA | SR. VP, MARKET ACCESS Highest-paid employee | 45 | $417,509 | $103,720 |
| KATHLEEN SCHOSTACK | SR. VP, PROGRAM & ALLIANCE MANAGEMENT Highest-paid employee | 45 | $432,300 | $86,259 |
| SALAH FORAIDA | SR. DIRECTOR, MEDICAL AFFAIRS Highest-paid employee | 45 | $430,090 | $52,408 |
| PIETRO O TURILLI | SR. VP, EXTERNAL AFFAIRS Key employee | 45 | $369,474 | $98,009 |
| RAJNEESH TANEJA | VP, PHARMACEUTICAL PRODUCT DEVELOPMENT Highest-paid employee | 45 | $370,728 | $80,940 |
| ARIEL PABLOS-MENDEZ | VICE-CHAIR Trustee or director, Officer | 3 | $0 | $0 |
| DAVID NORTON | CHAIR Trustee or director, Officer | 3 | $0 | $0 |
| AKSHAY VAISHNAW | DIRECTOR (AS OF 12/01/24) Trustee or director | 3 | $0 | $0 |
8 more people on this return
| Name | Title | Hours / week | Compensation |
|---|---|---|---|
| ANN TAYLOR | DIRECTOR (AS OF 09/01/24) Trustee or director | 3 | $0 |
| ERIC GOOSBY | DIRECTOR Trustee or director | 3 | $0 |
| KIM SCHWARTZ | DIRECTOR Trustee or director | 3 | $0 |
| MITCHELL WARREN | DIRECTOR Trustee or director | 3 | $0 |
| RASHA HIBRI | DIRECTOR Trustee or director | 3 | $0 |
| RATAN WATAL | DIRECTOR Trustee or director | 3 | $0 |
| SRISHTI GUPTA | DIRECTOR (AS OF 12/01/24) Trustee or director | 3 | $0 |
| SUNDAR KODIYALAM | DIRECTOR Trustee or director | 3 | $0 |
990 for the year ended December 31, 2023: 21 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| DR MELVIN SPIGELMAN | PRESIDENT/CEO Trustee or director, Officer | 45 | $921,007 | $107,776 |
| DR NADER FOTOUHI | SR. VP, CHIEF SCIENTIFIC OFF. Key employee | 45 | $545,570 | $114,466 |
| DR EUGENE SUN | SR. VP, RESEARCH & DEV'T Key employee | 45 | $562,265 | $86,040 |
| MARIA BEUMONT | VP, CHIEF MEDICAL OFFICER Key employee | 45 | $483,078 | $81,608 |
| COLLEEN PERO | SECRETARY/CAO Officer | 45 | $457,040 | $68,861 |
| ROBERT LORETTE | SR. VP, BUSINESS DEVELOPMENT Highest-paid employee | 45 | $437,313 | $83,939 |
| ANGELA VANDERPLOEG | TREASURER/CFO Officer | 45 | $411,013 | $100,307 |
| SANDEEP JUNEJA | SR. VP, MARKET ACCESS Highest-paid employee | 45 | $406,262 | $99,678 |
| KATHLEEN SCHOSTACK | SR. VP, PROG. & ALLIANCE MGMT Highest-paid employee | 45 | $419,997 | $82,950 |
| SALAH FORAIDA | SR. DIRECTOR, MEDICAL AFFAIRS Highest-paid employee | 45 | $418,194 | $50,829 |
| RAJNEESH TANEJA | VP, PHARMACEUTICAL PROD. DEV'T Highest-paid employee | 45 | $360,974 | $77,744 |
| PIETRO TURILLI | SR.VP, EXTERNAL AFFAIRS Key employee | 45 | $327,992 | $91,064 |
| DAVID NORTON | CHAIR Trustee or director, Officer | 3 | $0 | $0 |
| ARIEL PABLOS-MENDEZ | VICE CHAIR Trustee or director, Officer | 3 | $0 | $0 |
| ERIC GOOSBY | DIRECTOR Trustee or director | 3 | $0 | $0 |
| RASHA HIBRI | DIRECTOR Trustee or director | 3 | $0 | $0 |
| SUNDAR KODIYALAM | DIRECTOR Trustee or director | 3 | $0 | $0 |
| MARIO RAVIGLIONE | DIRECTOR Trustee or director | 3 | $0 | $0 |
| KIM SCHWARTZ | DIRECTOR Trustee or director | 3 | $0 | $0 |
| MITCHELL WARREN | DIRECTOR Trustee or director | 3 | $0 | $0 |
| RATAN WATAL | DIRECTOR eff. 1/1/2023 Trustee or director | 3 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 80 PINE STREET 20TH FLR, NEW YORK, NY 10005-1755
- In care of
- % ANGELA VANDERPLOEG
- Principal officer (990 for 2024)
- MELVIN SPIGELMAN, 80 PINE STREET FL 20, NEW YORK, NY 10005
- Signed the 990
- MELVIN SPIGELMAN, PRESIDENT/CEO
- Phone
- (212) 227-7540
- Website
- WWW.TBALLIANCE.ORG
- Return prepared by
- BDO USA
Mission
TB ALLIANCE IS A NOT-FOR-PROFIT ORGANIZATION DEDICATED TO THE DISCOVERY, DEVELOPMENT AND DELIVERY OF BETTER, FASTER-ACTING AND AFFORDABLE TUBERCULOSIS DRUGS THAT ARE AVAILABLE TO THOSE WHO NEED THEM.
Program accomplishments
- RESEARCH AND DEVELOPMENT - TB ALLIANCE IS A NOT-FOR-PROFIT PRODUCT DEVELOPMENT PARTNERSHIP (PDP), UNIQUELY POSITIONED TO LEVERAGE A GLOBAL NETWORK OF PUBLIC AND PRIVATE PARTNERS TO MOST EFFICIENTLY ADVANCE TB DRUG DEVELOPMENT. A PDP BUILDS PARTNERSHIPS BETWEEN THE PUBLIC, PRIVATE, ACADEMIC, AND PHILANTHROPIC SECTORS TO DRIVE THE DEVELOPMENT OF NEW PRODUCTS FOR UNDERSERVED MARKETS. PDPS RETAIN DIRECT MANAGEMENT OVERSIGHT OF THEIR PROJECTS, THOUGH MUCH OF THE LABORATORY AND CLINICAL WORK IS DONE THROUGH EXTERNAL RESEARCH FACILITIES AND CONTRACTORS. WE COMBINE THE RESEARCH AND DEVELOPMENT EXPERTISE OF OUR STAFF WITH THE SKILLS AND RESOURCES OF OUR PARTNERS TO HARNESS THE MOST PROMISING SCIENCE WHEREVER IT MAY EXIST AROUND THE WORLD. THIS MODEL MINIMIZES COSTS, INCLUDING OVERHEAD AND INVESTMENTS IN INFRASTRUCTURE, WHILE OPTIMIZING SCIENTIFIC CAPABILITY TO SPEED NEW TB DRUG DEVELOPMENT. OUR BUSINESS MODEL AND DIVERSE PARTNERSHIPS ALLOW TB ALLIANCE TO LEVERAGE ADDITIONAL PARTNER SERVICES FOR EVERY DOLLAR INVESTED IN ITS PROGRAMS. NC-009 - NC-009 IS A PAN-PHASE 2 CLINICAL TRIAL INCORPORATING ELEMENTS OF PHASE 2A, B, AND C TO EVALUATE THE SAFETY AND EFFICACY OF A COMBINATION OF A NEW EXPERIMENTAL COMPOUND, TBAJ-876, WITH PRETOMANID AND LINEZOLID, COMPONENTS OF TB ALLIANCE'S BPAL REGIMEN. THIS REGIMEN HAS THE POTENTIAL TO SHORTEN AND IMPROVE TREATMENT FOR BOTH DRUG-SENSITIVE AND DRUG-RESISTANT FORMS OF TB. RESULTS FROM PRECLINICAL AND PHASE 1 STUDIES WERE PRESENTED AT THE 2023 UNION CONFERENCE ON LUNG HEALTH AND SHOWED THAT THE NEW COMPOUND, TBAJ-876, WHEN COMPARED WITH BEDAQUILINE (A TB MEDICINE IN THE SAME DRUG CLASS), ELIMINATED TB BACTERIA FASTER AND HAD A POTENTIALLY SAFER PROFILE. NC-009 WILL TEST DIFFERENT DOSES OF TBAJ-876 IN COMBINATION WITH PRETOMANID AND LINEZOLID AGAINST THE CURRENT STANDARD OF CARE FOR DRUG-SENSITIVE TB - ISONIAZID, RIFAMPICIN, PYRAZINAMIDE, AND ETHEMBUTOL (HRZE). ANOTHER ARM OF THE TRIAL WILL ALSO TEST PRETOMANID AND LINEZOLID IN COMBINATION WITH BEDAQUILINE (BPAL), A REGIMEN NOW RECOMMENDED BY THE WORLD HEALTH ORGANIZATION TO TREAT SOME FORMS OF DR-TB, AGAINST DRUG-SENSISTIVE TB. THE STUDY ENROLLED APPRXIMATELY 300 PARTICIPANTS WITH DRUG-SENSITIVE TB AT 21 CLINICAL TRIAL SITES IN FIVE COUNTRIES: GEORGIA, PHILIPPINES, SOUTH AFRICA, TANZANIA, AND UGANDA. Q203 - TELACEBEC (Q203) IS A FIRST-IN-CLASS DRUG CANDIDATE AGAINST MYCOBACTERIUM TUBERCULOSIS INFECTION. Q203 TARGETS CYTOCHROME BC1 COMPLEX AND SHOWS POTENT ACTIVITY AGAINST MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB). Q203 HAS ALSO BEEN FOUND EFFECTIVE AGAINST BURULI ULCER (MYCOBACTERIUM ULCERANS), A CHRONIC, NECROTIZING DISEASE THAT AFFECTS SKIN AND SOMETIMES BONE AND CAN LEAD TO PERMANENT DEFORMITY AND LONG-TERM DISABILITY, AND LEPROSY (MYCOBACTERIUM LEPRAE). IN 2023, TB ALLIANCE IN-LICENSED Q203 FROM QURIENT, A CLINICAL-STAGE BIOTECHNOLOGY COMPANY BASED IN SOUTH KOREA. IN JULY 2024, A PHASE 2 PROOF-OF-CONCEPT STUDY WAS INITIATED TO EXPLORE THE USE OF TELACEBEC (Q203) TO TREAT BURULI ULCER. IF SUCCESSFUL, A SINGLE DRUG COULD CUT TREATMENT DURATION BY MORE THAN HALF. IN PARTNERSHIP WITH TB ALLIANCE AND WITH SUPPORT FROM QURIENT CO. LTD, PROFESSOR DANIEL O'BRIEN - A PROMINENT CLINICIAN-RESEARCHER AND EXPERT IN BURULI ULCER - IS LEADING THE STUDY AT BARWON HEALTH AND THE ROYAL MELBOURNE HOSPITAL IN AUSTRALIA. THE TRIAL WILL ENROLL APPROXIMATELY 40 ADULT PATIENTS WITH BURULI ULCER WHO WILL RECEIVE 28 DAYS OF TELACEBEC (300MG) ONCE DAILY, FOLLOWED BY A YEAR OF OBSERVATION. PRELIMINARY RESULTS ARE EXPECTED IN 2025. TBAJ-587 - THIS NEXT-GENERATION DIARYLQUINOLINE PROJECT HAS SHOWN POTENTIAL TO MAINTAIN BEDAQUILINE'S IMPRESSIVE ANTI-TB ACTIVITIES WHILE RETAINING ADDITIONAL IMPROVED PROPERTIES. TBAJ-587 IS BEING STUDIED THROUGH THE INNOVATIVE HEALTH INITIATIVE'S ERA4TB PROJECT AND, IN 2024, TBAJ-587 COMPLETED A PHASE I TRIAL DEMONSTRATING POSITIVE RESULTS. RESULTS PUBLICATIONS ARE UNDERWAY. SUTEZOLID - SUTEZOLID IS A PROMISING CLINICAL-STAGE TB DRUG CANDIDATE FROM THE OXAZOLIDINONE CLASS. TB ALLIANCE HAS IMPLEMENTED AN OPEN DEVELOPMENT APPROACH TO ADVANCE THE PHASE 2 TB DRUG CANDIDATE, SUTEZOLID, WHICH COULD BE A COMPONENT OF A NEXT-GENERATION TB REGIMEN. TB ALLIANCE HAS MADE SUTEZOLID AVAILABLE FOR STUDY BY ALL RESEARCHERS WHO COMMIT TO MAKING THEIR RESULTS AVAILABLE TO THE BROADER TB RESEARCH COMMUNITY. THIS NOVEL APPROACH HAS CONTRIBUTED TO THREE CLINICAL TRIALS THAT BEGAN IN 2023. PEERLINC - IN 2024, TB ALLIANCE LAUNCHED A NEW PEER-TO-PEER LEARNING FOR INNOVATIVE CURES (PEERLINC) KNOWLEDGE HUB BASED IN MANILA, WITH FUNDING FROM THE AUSTRALIAN GOVERNMENT THROUGH THE PARTNERSHIPS FOR A HEALTHY REGION INITIATIVE. PEERLINC, OPERATING IN PARTNERSHIP BETWEEN TB ALLIANCE AND THE TROPICAL DISEASE FOUNDATION, INC. (TDF), AND IN CLOSE COLLABORATION WITH THE DEPARTMENT OF HEALTH (DOH), PHILIPPINES, WILL HELP COUNTRIES IMPLEMENT BEST PRACTICES IN THE TREATMENT OF DRUG-RESISTANT TUBERCULOSIS (DR-TB) TO HELP SPEED THE WORLDWIDE PROGRAMMATIC IMPLEMENTATION OF INNOVATIVE, MORE EFFECTIVE TREATMENTS FOR THE DISEASE, STARTING WITH THE WORLD HEALTH ORGANIZATION (WHO)-RECOMMENDED SIX-MONTH, ALL-ORAL BPAL/M REGIMENS, COMPOSED OF THE ANTIBIOTICS BEDAQUILINE (B), PRETOMANID (PA), AND LINEZOLID (L), WITH OR WITHOUT MOXIFLOXACIN (M). PEERLINC WILL PROVIDE PRACTICAL TRAINING AND TECHNICAL ASSISTANCE TO COUNTRIES TO SUPPORT THIS OBJECTIVE, VIA EXPERTS FROM THE PHILIPPINES AND THE DEPARTMENT OF HEALTH, INCLUDING LUNG CENTER OF THE PHILIPPINES AND THE NATIONAL TB REFERENCE LABORATORY (NTRL). THE PHILIPPINES HAS SUCCESSFULLY AND RAPIDLY DEPLOYED NEW TREATMENTS THROUGH PARTICIPATION IN TB ALLIANCE'S LEVERAGING INNOVATION FOR FASTER TB TREATMENT (LIFT-TB) INITIATIVE. IN 2024 ALONE, THE PEERLINC KNOWLEDGE HUB COMPLETED TRAININGS WITH LEADERS, EXPERTS, AND STAFF FROM NATIONAL TB PROGRAMS IN SEVEN COUNTRIES: PERU, DRC, NIGERIA, BRAZIL, CAMBODIA, TANZANIA, RWANDA. LIFT-TB (LEVERAGING INNOVATION FOR FASTER TREATMENT OF TB) - THIS ACCESS PROGRAM, LAUNCHED IN 2020, SEEKS TO INCREASE TREATMENT COMPLETION RATES FOR DRUG-RESISTANT TB THROUGH ADOPTION AND SCALE UP OF NEW REGIMENS, BEGINNING WITH BPAL. IT FOCUSES ON SEVEN HIGH-BURDEN SOUTHEAST AND CENTRAL ASIAN COUNTRIES THAT SHOULDER APPROXIMATELY 1 IN 5 OF THE GLOBAL TB CASES. AS OF 2024, MORE THAN 100 COUNTRIES HAVE PROCURED THE SIX-MONTH, ALL-ORAL BPAL REGIMEN TO TREAT MORE THAN 180,000 PEOPLE WITH DRUG-RESISTANT TB. FAST TRACK THE CURE - IN SUPPORT OF THE WORLD HEALTH ORGANIZATION'S CALL TO ACTION TO ACCELERATE ACCESS TO SHORTER DR-TB CURES FOR ALL, THE FAST TRACK THE CURE MOVEMENT BRINGS COMMUNITIES AROUND THE WORLD TOGETHER TO RAISE AWARENESS AND FACILITATE ACCESS TO NEW DR-TB TREATMENTS, WHILE RAMPING UP ADVOCACY TO CONVINCE WORLD LEADERS THAT SIX-MONTH DR-TB CURES MUST BE WIDELY ADOPTED AND AVAILABLE TO ALL WHO NEED THEM. FAST TRACK THE CURE IS ALSO COLLABORATING CLOSELY WITH STOP TB TO ENSURE STRATEGIC ALIGNMENT AND PARTNERSHIP AND WITH THE CHALLENGE FACILITY FOR CIVIL SOCIETY MOVEMENT, BY ALIGNING WITH THEIR COMMUNITY ENGAGEMENT, CAPACITY BUILDING, AND DEMAND CREATION PILLARS AND FOCUS. SLASH-TB - TB ALLIANCE AND THE SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE HAVE DEVELOPED SLASH-TB (SAVINGS FROM LEVERAGING & ADOPTING SHORTER & HIGHLY EGGECTIVE TB TREATMENTS), A MODEL TO ESTIMATE COST SAVINGS FOR HEALTH SERVICE SYSTEMS, PATIENTS, FAMILIES, AND/OR CAREGIVERS WHEN USING THE BPAL/M REGIMENS AS COMPARED TO STANDARD DRUG-RESISTANT TB TREATMENTS.Expenses $47,923,018
- PUBLIC AFFAIRS AND POLICY - TB ALLIANCE MAINTAINS CRITICAL ALLIANCES WITH PUBLIC AND PRIVATE ORGANIZATIONS TO RAISE AWARENESS ABOUT TUBERCULOSIS ("TB") AND ADVOCATE FOR PUBLIC AND PRIVATE INVOLVEMENT IN RESEARCH FOR THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY FOR THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR ON THE DEVELOPMENT OF THESE MEDICINES. TB ALLIANCE CONTINUES TO PURSUE AN EXPLICIT COMMITMENT TO OUR "AAA MANDATE" - THAT ALL NEW PRODUCTS WILL BE ADOPTED, AVAILABLE AND AFFORDABLE TO THOSE WITH TB.Expenses $5,642,489 · grants $359,938
- BUSINESS DEVELOPMENT - TB ALLIANCE NEGOTIATES, IMPLEMENTS AND MANAGES AGREEMENTS WITH PUBLIC AND PRIVATE ORGANIZATIONS WORLDWIDE AND DOES SO BY ADHERING TO SOUND BUSINESS PRACTICES WHILE ENSURING THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY TO THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR TO HELP DEVELOP NEW MEDICINES FOR TB INDICATIONS.Expenses $852,237
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | December 31, 2025 | May 15, 2026 | Not on file |
| 2024 | December 31, 2024 | May 15, 2025 | 990 on file |
| 2023 | December 31, 2023 | May 15, 2024 | 990 on file |
IRS record
- EIN
- 13-4128413
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 2000
- Accounting year ends
- December
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Medical research (H80)
- Assets (IRS master file)
- $204,316,428
- Income (IRS master file)
- $202,456,266
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | December 2024 | $63,732,557 | $61,508,783 | $204,316,428 | IRS |
| 990 | December 2023 | $60,240,486 | $55,378,579 | $197,319,541 | XML |
| 990 | December 2022 | $56,212,963 | $55,785,890 | $176,686,879 | IRS |
| 990 | December 2021 | – | – | – | IRS |
| 990 | December 2020 | – | – | – | IRS |
| 990 | December 2018 | – | – | – | IRS |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 13-4128413).
Questions about GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC
- What is the EIN of GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC?
- The employer identification number (EIN) of GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC is 13-4128413.
- Is GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2000.
- Are donations to GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC due?
- The return for tax year 2025 (the year ending December 31, 2025) is due May 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended December 2024.
- Who is the principal officer of GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC?
- The 990 for the year ended December 31, 2024 names MELVIN SPIGELMAN.
- Who are the officers and directors of GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC?
- The 990 for the year ended December 31, 2024 lists 23 people; 12 received compensation from the organization, the highest $939,703 (DR MELVIN SPIGELMAN, PRESIDENT/CEO).
- How much revenue does GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC have?
- On its 990 for the year ended December 31, 2024 it reported revenue of $63,732,557, expenses of $61,508,783 and total assets of $204,316,428 at year end.
Other nonprofits in NEW YORK
- MICHAEL J FOX FOUNDATION FOR PARKINSONS RESEARCH EIN 13-4141945 · last filed 990 for 2025
- PUBLIC HEALTH SOLUTIONS EIN 13-5669201 · last filed 990 for 2025
- PARKINSONS FOUNDATION INC EIN 13-1866796 · last filed 990 for 2025
- LICR FUND INC EIN 13-3573053 · last filed 990 for 2024
- CARDIOVASCULAR RESEARCH FOUNDATION EIN 52-1752653 · last filed 990 for 2024
- INTERNATIONAL BRAIN RESEARCH ORGANIZATION EIN 88-4372025 · last filed 990 for 2024
- CANCER RESEARCH INSTITUTE INC EIN 13-1837442 · last filed 990 for 2025
- THE FOUNDATION FOR AIDS RESEARCH EIN 13-3163817 · last filed 990 for 2025